Solid Biosciences Inc. SLDB
Set alert
At close · Oct 30
After hours · Oct 30, 5:34 PM ET
- YTD
- +9.93%
- 1 year
- +16.76%
- Open
- 6.30
- Prev close
- 6.39
- Mkt cap
- 664.80M
- Vol
- 873.12K
- Avg vol
- 1.18M
- EPS
- -1.89
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.02
- High
- 6.42
- Forward P/E
- -5.46
- Beta
- 2.44
- Short ratio
- 17.18
- Inst. own
- 107.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 9.32
- 200-d avg
- 7.34
- 1y target
- 18.67
News
-
6 days ago benzinga.com
Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid’s commitment to the global development of SGT-212 for individuals living with Friedreich’s ataxia -- SGT-212 is a…
6 days ago globenewswire.com
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia
- Obtaining Orphan designation from the European Commission reflects Solid's commitment to the global development of SGT-212 for individuals living with Friedreich's ataxia - - SGT-212 is a…
6 days ago defenseworld.net
Solid Biosciences (SLDB) Expected to Announce Quarterly Earnings on Monday
Solid Biosciences (NASDAQ: SLDB - Get Free Report) is projected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of…
1 week ago globenewswire.com
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
-
2 weeks ago benzinga.com
UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
UBS analyst Joon Lee initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $20.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…
1 month ago globenewswire.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and…
1 month ago seekingalpha.com
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Solid Biosciences is a speculative buy, leveraging a differentiated SGT-003 gene therapy for Duchenne muscular dystrophy with a credible cash runway into mid-2028. SLDB's investment thesis centers on…
1 month ago benzinga.com
This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.
-
1 month ago benzinga.com
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
RBC Capital analyst Luca Issi initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Outperform rating and announces Price Target of $18.
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Solid Biosciences (NASDAQ:SLDB) with a Buy and maintains $25 price target.
1 month ago seekingalpha.com
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago globenewswire.com
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
2 months ago benzinga.com
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva…
-
2 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and raises the price target from $16 to $20.
2 months ago benzinga.com
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading…
-
2 months ago benzinga.com
Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 9.52 percent increase over losses of…
4 months ago seekingalpha.com
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds…
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
4 months ago benzinga.com
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
4 months ago seekingalpha.com
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and…
5 months ago globenewswire.com
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
5 months ago globenewswire.com
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines…
5 months ago globenewswire.com
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global…
6 months ago globenewswire.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and…
6 months ago globenewswire.com
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid…
6 months ago globenewswire.com
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy -…
6 months ago globenewswire.com
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for…
7 months ago defenseworld.net
Solid Biosciences (NASDAQ:SLDB) Stock Price Up 5.5% on Analyst Upgrade
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Truist Financial upgraded the stock to a strong-buy rating. The stock traded as high as $7.61 and last…
7 months ago benzinga.com
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.
7 months ago benzinga.com
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
7 months ago benzinga.com
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
8 months ago benzinga.com
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
11 months ago benzinga.com
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
11 months ago benzinga.com
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
1 year ago benzinga.com
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
1 year ago benzinga.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
-
1 year ago benzinga.com
'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
1 year ago benzinga.com
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session